Japan's former Emperor Akihito hospitalized to get new treatment for heart condition
Akihito was diagnosed in May with myocardial ischemia, an asymptomatic heart condition of reduced blood flow from the coronary arteries to the heart muscle. He has since been on medication to improve blood flow to his heart while avoiding excessive exercise and reducing liquid intake.
Akihito abdicated in 2019, handing over the Chrysanthemum Throne to his son, current Emperor Naruhito and now holds the title of Emperor Emeritus.
After two months on the medication, doctors found little improvement in Akinito's condition and decided to give him an additional treatment to alleviate the burden on his heart, the Imperial Household Agency said.
Monday's hospitalization was to carefully determine the right dose of the new medication to avoid side effects, while monitoring his heart by electrocardiogram and other examination, the IHA said.
In 2012, Akihito underwent a coronary artery bypass surgery. Three years ago, he was diagnosed with right heart failure caused by tricuspid valve insufficiency.
Akihito was seen in the back seat of a palace car, wearing a white surgical mask and accompanied by his wife, Empress Emerita Michiko, as he was taken to the hospital.
Palace officials said they couldn't say how long Akihito would have to be hospitalized.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
23 minutes ago
- Fox News
China deploys drones, insecticide, nets for mosquito-borne virus: Report
Fox News senior medical analyst Dr. Marc Siegel weighs in on coronavirus-like measures reportedly being taken in China due to a mosquito-related virus on 'The Ingraham Angle.'
Fox News
an hour ago
- Fox News
CDC issues travel warning amid Chikungunya outbreak in China
Fox News State Department correspondent Gillian Turner reports on the outbreak of Chikungunya in China, the response from the Chinese as well as the U.S. on 'Special Report.'
Yahoo
2 hours ago
- Yahoo
3 Asian Value Stocks Estimated To Be Up To 48.2% Below Intrinsic Value
As global markets grapple with renewed trade tensions and economic uncertainties, Asian equities present a mixed landscape, with some indices experiencing declines amid these challenges. In this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer potential value relative to their intrinsic worth. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xiaocaiyuan International Holding (SEHK:999) HK$10.24 HK$20.31 49.6% Xi'an NovaStar Tech (SZSE:301589) CN¥157.18 CN¥311.35 49.5% Ningbo Sanxing Medical ElectricLtd (SHSE:601567) CN¥22.79 CN¥45.51 49.9% Inspur Digital Enterprise Technology (SEHK:596) HK$10.34 HK$20.38 49.3% Insource (TSE:6200) ¥918.00 ¥1816.18 49.5% Hibino (TSE:2469) ¥2402.00 ¥4707.69 49% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.59 49.7% GEM (SZSE:002340) CN¥6.53 CN¥12.95 49.6% Devsisters (KOSDAQ:A194480) ₩46700.00 ₩93201.12 49.9% cottaLTD (TSE:3359) ¥441.00 ¥867.59 49.2% Click here to see the full list of 273 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Everest Medicines Overview: Everest Medicines Limited is a biopharmaceutical company focused on discovering, licensing, developing, and commercializing therapies and vaccines for critical unmet medical needs in Greater China and other Asia Pacific markets, with a market cap of HK$25.51 billion. Operations: The company generates revenue of CN¥706.68 million from its pharmaceuticals segment, focusing on therapies and vaccines in Greater China and other Asia Pacific regions. Estimated Discount To Fair Value: 33.2% Everest Medicines is trading at HK$72.7, significantly below its estimated fair value of HK$108.8, indicating potential undervaluation based on cash flows. The company recently raised HK$1.57 billion through a follow-on equity offering and has promising growth prospects with expected annual earnings growth of over 100%. Everest's NEFECON drug has received full approval in China for treating IgA nephropathy, enhancing its revenue potential as it expands into Asian markets. Our comprehensive growth report raises the possibility that Everest Medicines is poised for substantial financial growth. Delve into the full analysis health report here for a deeper understanding of Everest Medicines. Wuxi Zhenhua Auto PartsLtd Overview: Wuxi Zhenhua Auto Parts Co., Ltd. manufactures and sells auto parts in China, with a market cap of CN¥8.32 billion. Operations: Wuxi Zhenhua Auto Parts Co., Ltd. generates revenue through the production and distribution of automotive components within China. Estimated Discount To Fair Value: 48.2% Wuxi Zhenhua Auto Parts Ltd. is trading at CN¥33.9, significantly below its estimated fair value of CN¥65.45, showcasing potential undervaluation based on cash flows. The company anticipates revenue growth of 20.5% annually, outpacing the broader Chinese market's 12.6%. However, its dividend yield of 1.74% is not well covered by free cash flows, and while earnings are expected to grow significantly over the next three years, return on equity remains modest at a forecasted 18.7%. Our earnings growth report unveils the potential for significant increases in Wuxi Zhenhua Auto PartsLtd's future results. Click to explore a detailed breakdown of our findings in Wuxi Zhenhua Auto PartsLtd's balance sheet health report. Kunshan Kinglai Hygienic MaterialsLtd Overview: Kunshan Kinglai Hygienic Materials Co., Ltd. (SZSE:300260) operates in the hygienic materials sector, with a market capitalization of approximately CN¥14.45 billion. Operations: The company generates its revenue from various segments, including hygienic materials and related products. Estimated Discount To Fair Value: 37.1% Kunshan Kinglai Hygienic Materials Ltd. is trading at CN¥35.61, well below its estimated fair value of CN¥56.63, indicating substantial undervaluation based on cash flow analysis. The company's earnings and revenue are projected to grow significantly over the next three years, with earnings expected to increase by 47.86% annually, outpacing the broader Chinese market's growth rates. Despite this potential, it carries a high level of debt and recently approved a modest dividend payout for 2024. Upon reviewing our latest growth report, Kunshan Kinglai Hygienic MaterialsLtd's projected financial performance appears quite optimistic. Take a closer look at Kunshan Kinglai Hygienic MaterialsLtd's balance sheet health here in our report. Make It Happen Get an in-depth perspective on all 273 Undervalued Asian Stocks Based On Cash Flows by using our screener here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1952 SHSE:605319 and SZSE:300260. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
